University of California Davis MIND Institute
Welcome,         Profile    Billing    Logout  
 11 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Handen, Benjamin L
NCT05418023: Validation of a Salivary miRNA Diagnostic Test for ASD

Recruiting
N/A
6604
US
Salivary Collection, Adaptive Assessment, Medical and Demographic questionnaire, Autism Assessment, Intellectual Development Assessment
Quadrant Biosciences Inc., University of California, Irvine, Holland Bloorview Kids Rehabilitation Hospital, Children's Hospital of Philadelphia, MetroHealth Medical Center, University of Rochester, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, University of Pittsburgh, University of Massachusetts, Worcester, Children's Hospital Los Angeles, Prisma Health-Upstate, University of Virginia, State University of New York - Upstate Medical University, Rush University, Seattle Children's Hospital, Drexel University, Emory University
Autism Spectrum Disorder, Developmental Delay
07/23
07/23
Froehlich, Tanya E
HYP01, NCT06042257: Guanfacine for Hyperactivity in Children with Down Syndrome (HYPEbeGONE_DS)

Recruiting
2
60
US
Guanfacine Hydrochloride Immediate Release, Placebo
Rachel G. Greenberg, MD, MB, MHS, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hyperactivity in Children with Down Syndrome, Impulsivity in Children with Down Syndrome
11/25
02/26
Esbensen, Anna
HYP01, NCT06042257: Guanfacine for Hyperactivity in Children with Down Syndrome (HYPEbeGONE_DS)

Recruiting
2
60
US
Guanfacine Hydrochloride Immediate Release, Placebo
Rachel G. Greenberg, MD, MB, MHS, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hyperactivity in Children with Down Syndrome, Impulsivity in Children with Down Syndrome
11/25
02/26
POPS or POP02, NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Recruiting
N/A
5000
Canada, US
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:, Aminocaproic acid, Amiodarone, Bosentan, Budesonide, Cefdinir, Cefepime, Ceftazidime, Clindamycin, Clobazam, Dexamethasone, Dexmedetomidine, Dextroamphetamine/Amphetamine, Fosfomycin, Furosemide, Gabapentin, Guanfacine, Hydrocortisone, Labetalol, Meropenem, Metformin, Milrinone, Nalbuphine, Nicardipine, Nifedipine, Oseltamivir, Oxycodone, Risperidone, Sertraline, Sevelamer Carbonate / Sevelamer Hydrochloride, Spironolactone, Terbutaline, Tranexamic acid, Voriconazole, Zolpidem, Azithromycin, Lopinavir/Ritonavir, Ribavirin, Tocilizumab, Anakinra, Aspirin, Canakinumab, Colchicine, Interferon, Remdesivir, Ruxolitinib, Sarilumab, Abatacept, Infliximab
Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
09/26
09/27
Canty, Marie
HYP01, NCT06042257: Guanfacine for Hyperactivity in Children with Down Syndrome (HYPEbeGONE_DS)

Recruiting
2
60
US
Guanfacine Hydrochloride Immediate Release, Placebo
Rachel G. Greenberg, MD, MB, MHS, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hyperactivity in Children with Down Syndrome, Impulsivity in Children with Down Syndrome
11/25
02/26
Sargado, Sabrina
HYP01, NCT06042257: Guanfacine for Hyperactivity in Children with Down Syndrome (HYPEbeGONE_DS)

Recruiting
2
60
US
Guanfacine Hydrochloride Immediate Release, Placebo
Rachel G. Greenberg, MD, MB, MHS, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hyperactivity in Children with Down Syndrome, Impulsivity in Children with Down Syndrome
11/25
02/26

Download Options